Apontis Pharma AG (XTER:APPH) ROCE % : 4.63% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Apontis Pharma AG's annualized ROCE % for the quarter that ended in Jun. 2024 was 4.63%.

Apontis Pharma AG ROCE % Historical Data

The historical data trend for Apontis Pharma AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apontis Pharma AG ROCE % Chart

Apontis Pharma AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-14.65

-4.85

2.09

7.34

-29.30

Apontis Pharma AG Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial					9.27	5.44	-18.26	-42.44	4.63

Apontis Pharma AG ROCE % Calculation

Apontis Pharma AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-14.775	/	( ( (59.853 - 5.359)	+	(57.46 - 11.11) )	/ 2 )
	=	-14.775	/	( (54.494	+	46.35)	/ 2 )
	=	-14.775	/	50.422
	=	-29.30 %

Apontis Pharma AG's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	2.04	/	( ( (57.46 - 11.11)	+	(48.204 - 6.353) )	/ 2 )
	=	2.04	/	( ( 46.35	+	41.851 )	/ 2 )
	=	2.04	/	44.1005
	=	4.63 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Apontis Pharma AG (XTER:APPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Apontis Pharma AG ROCE % Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

APPH:Germany

Address

Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789

Website

https://www.apontis-pharma.de

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.

Executives

Thomas Milz	Board of Directors
Bruno Wohlschlegel	Board of Directors
Thomas Zimmermann	Chief Financial Officer
Karlheinz Gast	Board of Directors

Apontis Pharma AG Headlines

No Headlines